Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.21.6 (
thromboplastin
)
13,278
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The objective of this study was to determine if the thrombin inhibitors Argatroban and
DUP
714 could anticoagulate whole blood without influencing the analyses of blood gases, electrolytes, ionized calcium or CO-oximetry. The anticoagulant potency of
DUP
714 (0.5-68 micromol/l) and Argatroban (1.5-390 micromol/l) was evaluated using the activated partial
thromboplastin
time (APTT), prothrombin time (PT) and whole blood clot time (WBCT). APTT and the PT were measured using a Behring Fibrintimer. APTT was found to be more sensitive to prolongation by both of the thrombin inhibitors than were the PT or WBCT assays.
DUP
714 was found to a more potent anticoagulant than Argatroban.
DUP
714 anticoagulated specimens (>2.2 micromol/l) did not clot for at least 2 days, whereas Argatroban preserved specimens (390 micromol/l) clotted within 5.5 h of collection. No statistically significant changes in the measurement of pH, PCO2, PO2, Na, K, ionized calcium, oxyhaemoglobin, deoxyhaemoglobin, methaemoglobin or carboxyhaemoglobin (measured using a Corning 288 Blood Gas/Electrolyte Analyzer and a Coming 270 CO-oximeter) were detected in
DUP
714 (34 micromol/l) or Argatroban (390 micromol/l) anticoagulated whole blood specimens. In conclusion,
DUP
714 and Argatroban are suitable anticoagulants for preserving blood prior to blood gas and electrolyte analyses.
...
PMID:Evaluation of argatroban and DUP 714 as anticoagulants for blood gas, electrolyte and ionized calcium analyses. 1075 50